Pharmaceuticals
HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet
* Ivonescimab plus chemotherapy demonstrated a median PFS of 11.14 months, PFS HR=0.60, P < 0.0001. * The absolute difference in median PFS between the two groups was 4.24 months (ΔPFS = 4.24 months), indicating significantly prolonged progression-free survival with ivonescimab combination th...
2025-10-19 23:37
1307
Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia
SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Primary plasma cell leukemia (pPCL) is a rare and highly aggressive plasma cell malignancy, often associated with complex genetic abnormalities. There is currently no standard treatment regimens, and conventional therapies for multiple myeloma are typically...
2025-10-19 14:00
1503
Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
AMT-116 is a potential first-in-class CD44v9-directed Topoisomerase I inhibitor-based ADC AMT-116 demonstrated a favorable safety profile, with manageable hematologic and Gastrointestinal toxicities Promising efficacies were observed in patients with heavily pretreated EGFR Wild-type NSCLC and ...
2025-10-17 22:00
3481
FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States
* YUFLYMA® (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications – adolescent hidradenitis suppurativa (HS) and pediatric uveitis (UV), in the U.S.[1],[2] * Pediatric UV is a rare eye inflammation in children, representing 5–10% of all uveitis...
2025-10-17 13:32
1186
Clarity signs copper-67 Supply Agreement with Nusano
SYDNEY, Oct. 16, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Supp...
2025-10-16 21:04
1272
Cell Publishes Breakthrough Research Results of IASO Bio's Anti-BCMA CAR-T Equecabtagene Autoleucel in Autoimmune Disease Multiple Sclerosis
SHANGHAI, NANJING, China and PLEASANTON, Calif., Oct. 16, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies, today announced that theCell published results fr...
2025-10-16 20:45
1318
Unixell Biotech reported a case study of UX-DA001, an iPSC-derived autologous cell therapy for Parkinson Diseases at MDS Congress 2025
SHANGHAI, Oct. 16, 2025 /PRNewswire/ -- Unixell Biotech, a clinical-stage bitotech company focused on developing innovative cell therapies for Parkinson'sdisease (PD) and other neurological disorders, announced positive 6-month follow-up data from the first patient in its phase 1 clinical trial ...
2025-10-16 20:35
1251
HARMONi-6 Phase III Study of Ivonescimab Accepted by The Lancet and Selected for ESMO 2025 LBA Presentation
HONG KONG, Oct. 16, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) today announced that the groundbreaking results from the registrational Phase III AK112-306/HARMONi-6 study of ivonescimab have been accepted for publication in The Lancet. The study evaluated ivonescimab, a first-in-class PD-1/VEGF b...
2025-10-16 12:15
1238
Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline
BEIJING and SHANGHAI and BOSTON, Oct. 15, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) today announced that its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd. ("Beijing Jacobio"), has entered into a Capital Increase and Equity Transfer Agreement with Oceanpine Capital and an industry part...
2025-10-15 23:05
1865
Nona Biosciences Appoints Dr. Di Hong as Chief Executive Officer to Drive Technology Innovation and Strategic Growth
CAMBRIDGE, Mass., Oct. 14, 2025 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced the appointment of Dr. Di Hong as Chief Executive Officer (CEO). Dr. Hong will be based inShangh...
2025-10-15 08:00
1086
Mabwell Announces Latest Clinical Results of Novel B7-H3-Targeting ADC 7MW3711 to Be Presented at 2025 ESMO Congress
SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that clinical research results of its novel B7-H3-targeting ADC (R&D code: 7MW3711) for multiple advanced solid tumors, will be presented as a poster at the E...
2025-10-15 00:00
1391
Co-PSMA trial achieves primary endpoint
SYDNEY, Oct. 14, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT...
2025-10-14 21:03
1195
Kyoto University Engineering Ph.D. Team Achieves Technology Transformation in Chengdu; LivingPhoenix's Biomimetic Collagen Rated "International Leading-Edge"
—— Globally Pioneering POGMENT Triple-Helix Biomimetic Collagen Debuts at Chinese Biomaterials Congress 2025 CHENGDU, China, Oct. 14, 2025 /PRNewswire/ -- The 2025 Chinese Biomaterials Congress recently convened in Shaoxing,Zhejiang, bringing together a prestigious gathering of leading minds in ...
2025-10-14 20:30
953
Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from NMPA
SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received IND clearance from the National Medical Products Administration (NMPA) inChina to ini...
2025-10-14 20:00
893
Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults
-- Results indicate potential best-in-class RSV+hMPV±PIV3 combination vaccines, with the potential ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection-- -- Increases in neutralizing antibodies of approximately 6-8 fold for RSV, 6-9 fol...
2025-10-14 18:18
977
Thousand Oaks Biologics Shanghai ADC Site receives EU QP Declaration
SHANGHAI, Oct. 13, 2025 /PRNewswire/ -- Thousand Oaks Biologics' antibody-drug conjugate (ADC) manufacturing site successfully passed an audit conducted by a European Union Qualified Person (QP) and formally received a QP Declaration. This milestone certifies that the company's quality management...
2025-10-13 20:00
841
ReviR Therapeutics Receives Orphan Drug Designation from FDA for RTX-117 to Treat Charcot-Marie-Tooth Disease
BRISBANE, Calif. , Oct. 13, 2025 /PRNewswire/ -- ReviR Therapeutics, a biotech company focused on developing novel treatments for neurogenetic diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for RTX-117, its lead investigational...
2025-10-13 18:00
890
GC Biopharma Secures CMO Rights for Shingles Vaccine from Curevo Vaccine
YONGIN, South Korea, Oct. 13, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed an agreement with Curevo Vaccine to secure contract manufacturing (CMO) rights for amezosvatein (development name: CRV-101), a recombinant shin...
2025-10-13 12:38
989
Ascletis Selects a Best-In-Class Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for Clinical Development
- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC35 was approximately 14 days, 6-fold longer than tirzepatide, which supports once-monthly subcutaneous (SQ) dosing in humans. - In head-to-head NHP studies, drug exposures of ASC35 intravenous (I.V.) and SQ admin...
2025-10-13 08:10
1191
C-Ray Therapeutics (Chengdu) Co., Ltd Congratulates Partner Biokin Pharmaceutical on NMPA IND Approval of First Proprietary ARC Drug [177Lu]-BL-ARC001
CHENGDU, China, Oct. 11, 2025 /PRNewswire/ -- C-Ray Therapeutics (Chengdu) Co.,Ltd proudly congratulates its strategic partner,Biokin Pharmaceutical, on receiving implied approval from theNational Medical Products Administration (NMPA) for the clinical trial application of [177Lu]-BL-ARC001 Injec...
2025-10-11 20:45
2201
Week's Top Stories
Most Reposted
Senetas and Nokia Announce Strategic Alliance to Secure Mission-Critical Networks for Defence and Government
[Picked up by 312 media titles]
2025-11-27 07:25SpeQtre, the entanglement-based quantum comms demonstrator satellite, is now on orbit
[Picked up by 292 media titles]
2025-11-29 09:00
Pop the 90s: The Westin Surabaya and Four Points Pakuwon Indah Welcomes 2026 with a Spectacular Live Show Featuring Project Pop
[Picked up by 286 media titles]
2025-11-26 10:49
Lincah Acquires Orderfaz to Strengthen Southeast Asia's Social Commerce Infrastructure
[Picked up by 283 media titles]
2025-11-26 09:00
Singapore Hosts Record-Breaking World Robot Olympiad (WRO®) International Final 2025
[Picked up by 282 media titles]
2025-11-27 08:00
Most Read
LightInTheBox to Hold 2025 Annual General Meeting on December 19, 2025
2025-11-25 21:20
2844
MINISO Unveils Australia's First and Largest MINISO LAND Flagship at Sydney Chatswood
2025-11-27 18:56
2423
